Xitolong-OD Capsule SR contains Itopride 150 mg, a prokinetic agent indicated for the treatment of functional dyspepsia and other gastrointestinal motility disorders. Itopride acts by enhancing acetylcholine release through dopamine D2 receptor antagonism and inhibiting acetylcholinesterase activity, thereby promoting gastric emptying and improving gastrointestinal motility. This sustained-release formulation ensures prolonged therapeutic effects, allowing once-daily dosing and improved patient compliance. Xitolong-OD Capsule SR is effective in alleviating symptoms such as bloating, nausea, early satiety, and epigastric discomfort associated with delayed gastric emptying. It is particularly beneficial in patients with diabetic gastroparesis and functional dyspepsia where impaired motility contributes to symptomatology. The medication is generally well tolerated; common adverse effects may include mild diarrhea, abdominal cramps, or dizziness. It is contraindicated in patients with mechanical gastrointestinal obstruction, gastrointestinal hemorrhage, or hypersensitivity to Itopride or any excipients. Caution is advised in patients with liver or renal impairment. Xitolong-OD Capsule SR should be administered as prescribed by a healthcare professional, typically before meals to optimize efficacy. Regular monitoring and adherence to recommended dosage are essential to maximize therapeutic outcomes and minimize potential side effects.